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Objective: Children with congenital diaphragmatic hernia (CDH) are at risk for
pulmonary morbidity. Data on longitudinal evaluation of lung function in CDH are
scarce. We hypothesized that CDH patients would have impaired lung function that
worsens over time. We evaluated lung function and its determinants at ages 8 and 12
years.
Methods: Dynamic and static lung volumes, and diffusion capacity were measured.
Extracorporeal membrane oxygenation (ECMO) treatment, the standardized Eur-
opean neonatal treatment protocol, patch repair, duration of ventilation, type of
initial mechanical ventilation, and nitric oxide treatment were entered as covariates
in linear mixed models with standard deviation score (SDS) lung function parameters
(FEV1, FEF25‐75, and KCO) as dependent variables.
Results: Seventy‐six children (27 ECMO‐treated) born between 1999 and 2009
performed 113 reliable lung function tests. Severity of airflow obstruction
deteriorated significantly from age 8 to 12 years: estimated mean difference (95%
confidence interval [CI]) SDS FEV1 was −0.57 (−0.79 to −0.36) and SDS FEF25‐75 was
−0.63 (−0.89 to −0.37), both P < .001. Static lung volumes were within normal range
and unchanged over time: estimated mean difference (95% CI) SDS TLC −0.27 (−0.58
to 0.04); P = .085. SDS KCO was below normal at 8 and 12 years and remained stable:
−0.06 (−0.22 to 0.35); P = .648. These observations were irrespective of ECMO
treatment. FEV1 and FEF25‐75 were negatively associated with duration of ventilation
(P < .001). Baseline data were not related with TLC or KCO.
Conclusions: CDH patients should be followed into adulthood as they are at risk for
worsening airflow obstruction and decreased diffusion capacity at school age,
irrespective of ECMO treatment.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
K E YWORD S
congenital diaphragmatic hernia, determinants, extracorporeal membrane oxygenation, long-
itudinal evaluation, lung function, respiratory morbidity
1 | INTRODUCTION
Congenital diaphragmatic hernia (CDH) combines a develop-
mental defect of the diaphragm with pulmonary hypoplasia,
abnormal pulmonary vascular development, increased vasoreac-
tivity,1 and increased susceptibility for chronic lung disease.2
Advances in surgical and neonatal management, and the im-
plementation of a standardized European CDH neonatal treat-
ment protocol since November 20073 (referred to as “postnatal
treatment protocol”) (Table S1), have significantly contributed to
improved survival, with reported rates from 68% to 90%.2,4 The
increase in survival may lead to an increase in morbidity for the
survivors.
Pulmonary morbidity in CDH patients is common.5,6 Lung
hypoplasia with persistent airflow obstruction,7,8 iatrogenic lung
damage due to mechanical ventilation, and microstructural
changes in the lung9 are factors that may contribute to long‐term
pulmonary morbidity. While normal lung tissue continues to
develop alveoli into adolescence,10,11 it is unknown if and when
catch‐up growth of the abnormal lungs of CDH patients will
occur.12 Besides, several studies have shown that these patients’
lung development is affected by inhibited pulmonary vascular
growth.13,14
Besides these structural pulmonary abnormalities, CDH patients
suffer from gastrointestinal and respiratory problems. Gastroeso-
phageal reflux and recurrent episodes of lower respiratory tract
infections often occur not only in the first years after birth, but also
later in life.15-17 All these together may lead to decreased lung
function at school age.
A previous study from our group found hyperinflation of the
lungs with larger functional residual capacity and decreased
expiratory flows in CDH patients’ first year of life, especially
among those treated with extracorporeal membrane oxygenation
(ECMO).18 While a few studies found normal pulmonary function
later on,19 other studies showed airflow obstruction, high
prevalence of increased airway responsiveness and decreased
diffusion capacity in CDH patients.6,8,20,21 However, many of these
studies often have a cross‐sectional design and evaluated lung
function in CDH patients born several decades ago. As since then
important advances in surgical and neonatal management have
been made, including the implementation of the CDH Euro
Consortium postnatal treatment protocol in November 2007,3
more recent data on lung function need to be evaluated long-
itudinally over time.
Therefore, we longitudinally evaluated CDH patients’ lung
function at the ages of 8 and 12 years. A secondary aim was to gain
insight into the clinical determinants of lung function and the
effect of the use of the postnatal treatment protocol.
2 | MATERIALS AND METHODS
2.1 | Patients, procedures, and study design
We included all children born with CDH between January 1999 and June
2009 who joined the standardized prospective follow‐up program at the
Erasmus MC‐Sophia Children’s Hospital according to the present
standard of care for children born with major anatomical congenital
anomalies. These children and their parents are followed by a multi-
disciplinary team, and eight standardized assessments are performed
from the ages of 6 months to 17 years as published by our research
group.22,23 We analyzed data of children who had been clinically stable
for at least 3 weeks before the assessment of the follow‐up program at
ages 8 and 12 years and who performed reproducible lung function tests.
We excluded data from patients diagnosed with CDH after 7
days of age, those with paraesophageal diaphragmatic defects,
those with a diaphragmatic eventration, and those with an
unreliable lung function test. Until November 2007, ECMO
treatment was applied in cases of reversible severe respiratory
failure by using the entry criteria as reported by Stolar et al.24
After November 2007, children were treated according to the
standardized CDH EURO Consortium consensus treatment pro-
tocol which included ECMO criteria3 (Table S1). These criteria
were no different from earlier criteria.
The children were seen by a team of dedicated team of physicians
and allied health professionals. A pediatrician and a pediatric surgeon
performed standardized physical examinations. Lung function was
measured by a specialized technician. Perinatal and demographic
characteristics were retrieved from medical records.
All data were collected during routine care and subjects were not
submitted to any handling and no rules of human behavior were
imposed. Therefore, institutional review board approval was waived
(MEC‐2016‐111). Parents of all children were routinely informed
about the study and provided permission to use the deidentified data
for research purposes.
2.2 | Measurements
2.2.1 | Baseline data
The following baseline data were recorded: sex, age, gestational age,
birth weight, ethnicity, side of hernia, type of repair, duration of
mechanical ventilation, ventilation‐free days in the first 28 days of
life, nitric oxide (NO) treatment, type of initial mechanical ventilation,
duration of intensive care unit stay, duration of initial hospital stay,
presence of chronic lung disease (CLD),25 congenital cardiac
anomalies, treatment with phosphodiesterase type 5 inhibitor
(PDE5 treatment), β‐2‐mimetica, prophylactic inhaled corticosteroid,
atopy, number of respiratory tract infections in the previous year
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treated with antibiotics prescribed by a family physician, local
pediatrician or pediatric pulmonologist, treatment with prophylactic
antibiotics, bronchodilators, symptoms of gastroesophageal reflux
(heartburn, chest pain, regurgitation, nocturnal cough, dysphagia, and
dysphonia), Nissen fundoplication, tube feeding, and dietetics.
2.2.2 | Lung function measurement
Airway patency was assessed with an electronic spirometer
(Masterscreen PFT; Carefusion; San Diego, CA) before and after
inhalation of 400 μg salbutamol.26 Children using inhalation medica-
tion had been instructed to stop short‐acting β2‐agonists 8 hours
before and long‐acting β2‐agonists 24 hours before assessment.
Forced expiratory volume in 1 second (FEV1), forced vital capacity
(FVC), FEV1/FVC and forced expiratory flows between 25% and 75%
of vital capacity (FEF25‐75) were expressed as absolute values, and as
SDS based on sex‐, age‐, and length‐related reference values.27
Reversible airway obstruction was defined as an increase of
FEV1 > 11% after bronchodilatation (BD).
28
Total lung capacity (TLCpleth), RV/TLCpleth ratio, and functional
residual capacity (FRCpleth) were determined by whole body plethysmo-
graphy (Masterscreen Body Plethysmography; Carefusion) and ex-
pressed as absolute values and percentile scores. Diffusion capacity for
carbon monoxide (DLCO) and diffusion capacity corrected for alveolar
volume (KCO) were measured using a multigas analyzer (Masterscreen
PFT; Carefusion) by the single‐breath method. Percentile scores for
static lung volumes and diffusion capacity obtained by the sex‐, age‐,
and length‐related reference equations of Koopman et al29 were
transformed into SDS using an inverse normal transformation.
The fraction of exhaled NO (FeNO) was measured online using
the NIOX analyzer (Aerocrine, Solna, Sweden) according to pre-
viously described guidelines and compared against the American
Thoracic Society cutoff point.30,31
Equipment and procedures fulfilled European Respiratory Society
criteria.26
2.3 | Statistical analysis
Differences in baseline data between “participants in the follow‐up
program” and “nonparticipants in the follow‐up program” and the
children “treated with neonatal ECMO” and “not treated with
neonatal ECMO” were evaluated using the Mann‐Whitney U tests
for continuous variables and χ2 tests for categorical variables. To
evaluate lung function parameters (spirometry, body plethysmogra-
phy, and diffusion capacity) longitudinally and to compare these lung
function parameters of patients with the norm population (SDS = 0),
we used linear mixed models. This method can account for within‐
subject correlations and allows for missing values in the dependent
variable.32 To test whether lung function parameters differ between
ECMO‐treated and non–ECMO‐treated CDH patients, Mann‐Whit-
ney U tests were used. To investigate whether perinatal and
demographic characteristics had a significant influence on SDS lung
function parameters (FEV1 after BD, FEF25‐75 after BD and KCO), we
considered the following baseline data in the linear mixed model as
covariates: ECMO treatment, postnatal treatment protocol, patch
repair, log transformation of duration of ventilation, type of initial
mechanical ventilation, and NO treatment. Independent variables
with P > .20 for all outcomes were removed from the model. The two‐
way interaction effect between timepoint of assessment and log
duration of ventilation or timepoint of assessment and ECMO
treatment was added to the resulting model if the interaction effect
was statistically significant (P < .05). The results of the linear mixed
models are reported using estimated marginal means, which are the
predicted values of the dependent variable adjusted for the effect of
covariates. Multicollinearity was assessed using variance inflation
factors (VIFs). VIFs < 3.0 were considered acceptable, whereas higher
values were taken as a sign of multicollinearity. Analyses were
performed using SPSS 24.0 (IBM, Chicago, IL), and all statistical tests
used a two‐sided significance level of 0.05.
3 | RESULTS
3.1 | Patients
Between January 1999 and June 2009, 167 neonates were born with
CDH in the Erasmus MC‐Sophia Children’s Hospital. Forty‐seven
(27.6%) died. Forty‐one (34.2%) of the 120 survivors were excluded
for various reasons, mainly because of psychomotor retardation/
syndrome (n = 9), late diagnosis (n = 10) or they were lost to follow‐
up/ refused to visit our follow‐up (n = 13) (Figure 1). Seventy‐six
(96.2%) (8 years only, n = 39; 8 and 12 years, n = 37) of the 79
children who were eligible for follow‐up performed a reliable lung
function test (113 measurements) of whom 27 (35.5%) had received
ECMO treatment (Figure 1).
No significant differences in background characteristics, except
for ethnicity (P = .001) and side of hernia (P = .021), were found
between the participants and nonparticipants of our follow‐up
program (data not shown).
Patient characteristics are presented in Tables 1 and 2.
Compared to those without ECMO treatment, children who received
ECMO treatment were ventilated longer, had a higher incidence of
CLD, had a longer hospital stay, needed more often patch repair,
were more frequently treated with PDE5 and an atopic history was
reported more frequently at 8 years.
3.1.1 | Lung function
SDS FEV1, SDS FEV1/FVC, and SDS FEF25‐75, before and after
bronchodilation were significantly below normal at the ages of 8 and
12 years (Table 3; all P ≤ .01). Twenty‐four children (31.6%) had
reversible airflow obstruction at 8 years; nine had been treated with
ECMO (one‐third of all 8‐year‐old ECMO‐treated neonates). Hyper-
reactivity did not change over time: 11 children (29.7%) had reversible
airflow obstruction at 12 years; six of them had been treated with
ECMO (one‐third of all 12‐year‐old ECMO‐treated neonates).
TOUSSAINT‐DUYSTER ET AL. | 1259
Airflow obstruction had deteriorated significantly from 8 to 12
years (Table 4). This phenomenon was irrespective of ECMO
treatment (Tables 4,S2 and Figure 2).
Although spirometry results differed significantly between
ECMO and non‐ECMO patients (Table 2)—with lower spirometry
results in ECMO‐treated patients—ECMO had no significant effect
on the deterioration of spirometry parameters (FEV1 and FEF25‐75).
These two groups showed a similar trend in deterioration (Figure 2).
Static lung volumes, except for RVpleth and RV/TLCpleth ratio,
were within normal ranges at ages 8 and 12 years (Table 3). Diffusion
capacity, either corrected or uncorrected for alveolar volume, was
significantly below normal in both groups and ages (both P ≤ .001;
Table 3) and had not changed significantly over time (Table 4).
The median interquartile range (IQR) FeNO of 51 successful
measurements at 8 years was 10 (9‐15) ppb. The majority of children
(84.4%) had FeNO less than 20 ppb.
The median (IQR) FeNO of 33 successful measurements at
12 years was 14 (9‐27) ppb. More than two‐thirds of children (69.7%)
had FeNO less than 20 ppb (Table S1).
3.1.2 | Associations between lung function
parameters and baseline data
Duration of initial hospital stay and ventilation‐free days were
excluded as independent variables from the linear mixed model
because the VIFs were more than 3.0. VIFs of the other covariates
F IGURE 1 Study inclusion flowchart: achromosome aberration (n = 1), Cohen syndrome (n = 1), Loeys‐Dietz syndrome (n = 1),
Simpson‐Golabi‐Behmel syndrome (n = 2), Wolf‐Hirschhorn syndrome (n = 1), autism (n = 1), polymyalgia rheumatica (n = 2); bno lung function
test performed due to a tracheacanule (n = 1), organizational reasons (n = 1); cunreliable lung function test due to insufficient technique (n = 3).
BD, bronchodilatation; CDH, congenital hernia diaphragmatic; ECMO, extracorporeal membrane oxygenation; NO, nitric oxide
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were all less than 2.1 after removing these two independent
variables.
The independent variables type of repair, type of initial
ventilation and NO treatment were removed from the linear mixed
model, because of P values above the cutoff of .20.
FEV1 after BD was negatively associated with log duration of
ventilation (estimated coefficient [95% CI]: −0.865 [−1.215 to
−0.515], P < .001) (Figure 2 and Table S2). The FEV1 after BD of
children not treated with the postnatal treatment protocol was
significantly higher than that of children treated with this protocol
(0.767 [0.104 to 1.430], P = .024) (Tables S2,3). No other
significant association was found between FEV1 and baseline data
(Table S2). Besides, no significant interaction effects were found
between timepoint of assessment and log duration of ventilation
or timepoint of assessment and ECMO treatment for FEV1 (data
not shown).
FEF25‐75 after BD had a negative association with log duration
of ventilation (estimated coefficient [95% CI]: −0.827 [−1.162 to
−0.491], P < .001) (Figure 2 and Table S2). FEF25‐75 after BD of
children not treated with the postnatal treatment protocol was
significantly higher than that of children treated with the protocol,
(0.717 [0.053 to 1.380], P = .035) (Tables S2,3). No other
TABLE 1 Patient characteristics
Total (n = 76) ECMO (n = 27) Non‐ECMO (n = 49) P value
Background
Gestational age (wk) 39.0 ± 1.5 39.0 ± 1.5 38.7 ± 1.6 0.225
Birth weight (kg) 3.1 ± 0.4 3.1 (0.4) 3.0 ± 0.6 0.204
Male (%) 41 (53.9) 18 (66.7) 23 (46.9) 0.099
Ethnicity 0.129
Dutch (%) 64 (84.2) 21 (77.8) 43 (87.8)
Other (%) 12 (15.8) 6 (22.2) 6 (12.2)
Left‐sided hernia (%) 68 (89.5) 25 (92.6) 43 (87.8) 0.511
Patch repair (%) 54 (71.1) 23 (85.2) 31 (63.3) 0.044
Days of mechanical ventilation 15 (7‐24) 28 (15‐48) 10 (6‐18) <0.001
Ventilator‐free daysa 13 (0‐21) 0 (0‐12) 18 (10‐23) <0.001
Type of initial mechanical ventilation 0.843
CMV 33 (43.4) 12 (44.4) 21 (42.9)
HFO 41 (53.9) 14 (51.9) 27 (55.1)
Missing 2 (2.6) 1 (3.7) 1 (2.0)
Nitric Oxide treatment (%) 107 (56.0) 64 (95.5) 43 (34.7) <0.001
Days of ICU stay 24 (16‐51) 52 (28‐77) 19 (13‐33) <0.001
Days of initial hospital stay 39 (23‐63) 77 (36‐99) 29 (20‐51) <0.001
Chronic lung diseaseb (%) <0.001
No 45 (59.2) 8 (29.6) 37 (75.5)
Mild 14 (18.4) 3 (11.1) 11 (22.4)
Moderate 5 (6.6) 5 (18.5) ⋯
Severe 11 (14.5) 10 (37.0) 1 (2.0)
Missing 1 (1.3) 1 (3.7) ⋯
Congenital heart diseasec 7 (9.2) 4 (14.8) 3 (6.1) 0.210
PDE5 treatment 9 (11.8) 7 (25.9) 2 (4.1) 0.005
Data are presented as mean ± SD, median (IQR or number [percentage]) as appropriate.
Abbreviations: CDH, congenital diaphragmatic hernia; CMV, conventional mechanical ventilation; ECMO, extracorporeal membrane oxygenation; HFO,
high frequency oscillation; ICU, intensive care unit; IQR, interquartile range; PDE5 treatment, treatment with phosphodiesterase type 5 inhibitor.
a Ventilator‐free days in the first 28 days of life.
b Mild means requiring at least 28 days of supplemental oxygen therapy and discharge or termination of supplemental oxygen therapy by 36 weeks
postmenstruation age; Moderate means requiring at least 28 days of supplemental oxygen therapy with less than 30% oxygen at 36 weeks
postmenstruation age; Severe means requiring at least 28 days of supplemental oxygen therapy with 30% oxygen or greater at 36 weeks
postmenstruation age.
cCongenital heart disease: ventricle septum defect and atrium septum defect (n = 1); double outlet right ventricle + transposition blood vessel + open
foramen ovale + open ductus botalli (n = 1); open ductus botalli + open foramen ovale + tricuspidalis and mitral insufficiency (n = 1); open ductus
botalli + atrium septum defect with surgery (n = 3); and dysplastic pulmonic valve and tricuspidalis insufficiency (n = 1).
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significant associations were found between FEF25‐75 and baseline
data (Table S2). Besides, no significant interaction effects were
found between timepoint of assessment and log duration of
ventilation or timepoint of assessment and ECMO treatment for
FEF25‐75 (data not shown).
No significant associations were found between KCO and baseline
data (Table S2).
4 | DISCUSSION
This longitudinal follow‐up study in school‐aged children born with
CDH revealed deterioration of severity of airflow obstruction from 8
to 12 years, though reduced diffusion capacity corrected for alveolar
volume remained stable. These findings were irrespective of ECMO
treatment. The static lung volumes were within normal ranges and
did not change from 8 to 12 years. Longer duration of mechanical
ventilation was associated with significantly more airflow
obstruction.
Most studies that have evaluated pulmonary morbidity in school‐
aged children with CDH were cross‐sectional and revealed airflow
obstruction.6,8,20,21,33 The study populations of Haliburton et al21 and
Turchetta et al33 overlapped in birth years with our study population.
C ross‐sectional data from Haliburton et al were obtained from
retrospective chart analysis and only 33 of 118 patients (28%) had
reproducible pulmonary function tests. Their mean age was
11.3 ± 3.4 years. Sixty‐three percent of these children vs 57% in
our study had reduced FEV1 and 52% vs 59% had reduced FEV1/FVC.
In the cross‐sectional study of Turchetta et al, only 30 children of the
210 survivors were randomly selected to be enrolled in the study, of
whom 18 participated. The mean age of this study population was
6.6 ± 2.6 years. Contrary to our study, the mean FEV1 reached the
lower range of normal. Twenty‐two percent of the children had a
significant increase of FEV1 after bronchodilation vs 30% of the
children in our study. Differences in study design, selection of
subjects and numbers of subjects may explain differences between
these studies and our results. Selection bias might have occurred in
both previous cross‐sectional studies.
To our knowledge, only our group has previously reported on
longitudinal lung function in children and young adults who survived
CDH.6,7 In a study of ECMO‐treated patients with small numbers of
CDH patients, lung function had deteriorated over time at school
age.7 In a cohort born before ECMO was introduced in the
Netherlands (1991), mild airflow obstruction had deteriorated from
childhood to young adulthood.6 Microstructural pulmonary changes
not only in the ipsilateral lung but also in the contralateral lung were
found in nonsmoking young adults in this cohort.9 Taking into
account the very short duration of mechanical ventilation in this
older group6 and the change in mortality rates over time,2 we assume
that children with CDH who survived in the past decade suffered
from more severe lung hypoplasia, were ventilated longer, and have
more airflow obstruction. As we show in this study, deterioration of
airflow obstruction between 8 and 12 years, and in a previous study
of our research group deterioration of airflow obstruction from
childhood to adulthood,6 we recommend further research on long‐
term pulmonary morbidity including assessment of exercise toler-
ance and lung morphology. Lung perfusion scans revealed that
pulmonary vascular development in CDH patients remains abnor-
mal.14 These patients’ lung development is affected by inhibited
pulmonary vascular growth. Pulmonary vascular catch‐up growth
does not always occur, especially not in the ipsilateral lung.10,13,14




At 8 y of age n = 76 n = 27 n = 49
β‐2‐Mimetica 7 (9.2) 4 (14.8) 3 (6.1) .207
Daily 1 (1.3) ⋯ 1 (2.0)
Taken as needed 6 (7.9) 4 (14.8) 2 (4.1)
Inhaled corticosteroid
treatment
3 (3.9) 1 (3.7) 2 (4.1) .935
Atopic history 9 (11.8) 6 (22.2) 3 (6.1) .029
Gastroesophageal refluxa 13 (17.1) 4 (14.8) 9 (18.4) .689
Lower respiratory
infections past year with
antibiotics
2 (2.6) ⋯ 2 (4.1) .287
Prophylactic antibiotics 1 (1.3) ⋯ 1 (2.0)
Therapeutic antibiotics 1 (1.3) ⋯ 1 (2.0)
>1 therapeutic course 1 (1.3) ⋯ 1 (2.0)
Nissen fundoplication 10 (13.2) 5 (18.5) 5 (10.2) .274
Tube feeding ⋯ ⋯ ⋯ ⋯
Dietitian 5 (6.6) 2 (7.4) 3 (6.1) .829
At 12 y of age n = 37 n = 18 n = 19
β‐2‐Mimetica 5 (13.5) 4 (22.3) 1 (5.3) .286
Daily 1 (2.7) 1 (5.6) ⋯
Taken as needed 4 (10.8) 3 (16.7) 1 (5.3)
Inhaled corticosteroid
treatment
2 (5.4) 2 (11.1) ⋯ .179
Atopic history 7 (18.9) 5 (27.8) 2 (10.5) .153
Gastroesophageal refluxa 4 (10.8) 1 (5.6) 3 (15.8) .222
Lower respiratory
infections past year with
antibiotics
3 (8.1) 1 (5.6) 2 (10.5) .512
Prophylactic antibiotics ⋯ ⋯ ⋯
Therapeutic antibiotics 3 (8.1) 1 (5.6) 2 (10.5)
>1 therapeutic course ⋯ ⋯ ⋯
Nissen fundoplication 7 (18.9) 5 (27.8) 2 (10.5) .181
Tube feeding ⋯ ⋯ ⋯
Dietary intervention 1 (2.7) 1 (5.6) ⋯ .298
Data are presented in number (percentage)
Abbreviation: ECMO, extracorporeal membrane oxygenation.
aSymptoms of gastroesophageal reflux (heartburn, chest pain, regurgita-
tion, nocturnal cough, dysphagia, and dysphonia).
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Lung hypoplasia with limited catch‐up growth and vascular mal-
development will probably contribute to the development of CLD
and affect lung function later in life.
We assume that ECMO‐treated CDH patients have more severe
lung hypoplasia, pulmonary hypertension and vascular maldevelopment
than non–ECMO‐treated CDH patients. Therefore, they may need
longer mechanical ventilation, which is associated with risk of CLD. This
may be reflected by more severe airflow obstruction at school age.
The ECMO‐treated CDH patients in this study indeed had longer
duration of mechanical ventilation and more often CLD. They also
had significant lower spirometry parameters than non–ECMO‐
treated CDH patients. However, the change of airflow obstruction
over time was not affected by ECMO treatment.
This suggests that CLD could be responsible for the lower
spirometry parameters at school age, but not for the deterioration of
these parameters. Therefore, we recommend that future research
should focus on long‐term longitudinal assessment of pulmonary
morbidity and imaging of lung morphology into adulthood.
Interestingly the airflow obstruction in the children treated after
introduction of the postnatal treatment protocol was more severe
than that in the children born earlier. This result supports the
aforementioned assumption that with the decreased mortality from
TABLE 3 Lung function of CDH patients treated with and without ECMO
Total ECMO Non‐ECMO P valuea
8 y of age n = 76 n = 27 n = 49
SDS FVC before BD −0.44 (−0.74 to −0.14)** −0.96 (−1.56 to −0.36)* −0.15 (−0.46 to 0.17) .023
SDS FVC after BD −0.15 (−0.46 to 0.16) −0.61 (−1.24 to 0.02) 0.10 (−0.22 to 0.42) .033
SDS FEV1 before BD −1.06 (−1.37 to −0.76)* −1.60 (−2.19 to −1.01)* −0.77 (−1.10 to −0.43)* .006
SDS FEV1 after BD −0.51 (−0.84 to −0.19)* −1.08 (−1.77 to −0.39)* −0.21 (−0.52 to −0.10) .010
SDS FEV1/FVC before BD −1.04 (−1.35 to −0.73)* −1.09 (−1.60 to −0.59)* −1.00 (−1.41 to −0.60)* .903
SDS FEV1/FVC after BD −0.69 (−0.98 to −0.39)* −0.95 (−1.54 to −0.35)* −0.55 (−0.87 to −0.22)* .279
SDS FEF25‐75 before BD −1.53 (−1.82 to −1.23)* −1.77 (−2.32 to −1.22)* −1.38 (−1.74 to −1.04)* .332
SDS FEF25‐75 after BD −0.94 (−1.26 to −0.63)* −1.42 (−2.03 to −0.82)* −0.67 (−1.03 to −0.32)* .061
SDS RVpleth 0.56 (0.30 to 0.82)* 0.85 (0.25 to 1.45)* 0.39 (0.16 to 0.63)* .049
SDS TLCpleth −0.00 (−0.30 to 0.30) −0.16 (−0.78 to 0.47) 0.09 (−0.25 to 0.43) .686
SDS RV/TLCpleth 0.68 (0.42 to 0.94)* 1.00 (0.44 to 1.56)* 0.49 (0.22 to 0.76)* .009
SDS FRCpleth 0.13 (−0.07 to 0.34) 0.12 (−0.29 to 0.53) 0.13 (−0.11 to 0.37) .499
SDS DLCO −0.91 (−1.25 to −0.58)* −1.39 (−1.78 to −1.00)* −0.72 (−1.16 to −0.27)* .008
SDS KCO −1.29 (−1.52 to −1.05)* −1.61 (−2.10 to −1.12)* −1.15 (−1.41 to −0.88)* .130
12 y of age n = 37 n = 18 n = 19
SDS FVC before BD −0.61 (−1.01 to −0.21)* −1.06 (−1.75 to −0.38)* −0.37 (−0.92 to 0.17) .175
SDS FVC after BD −0.46 (−0.85 to −0.06)* −0.72 (−1.43 to −0.11)*** −0.38 (−0.91 to 0.14) .325
SDS FEV1 before BD −1.64 (−1.97 to −1.30)* −2.14 (−2.64 to −1.64)* −1.43 (−1.94 to −0.92)* .014
SDS FEV1 after BD −0.99 (−1.36 to −0.63)* −1.53 (−2.18‐−0.88)* −0.73 (−1.20 to −0.27)* .018
SDS FEV1/FVC before BD −1.63 (−2.01 to −1.25)* −1.85 (−2.40 to −1.30)* −1.43 (−1.98 to −0.87)* .245
SDS FEV1/FVC after BD −0.94 (−1.31 to −0.56)* −1.51 (−2.03 to −0.98)* −0.42 (−0.94 to 0.10) .055
SDS FEF25‐75 before BD −2.16 (−2.50 to −1.82)* −2.56 (−3.11 to −2.02)* −1.86 (−2.29 to −1.43)* .038
SDS FEF25‐75 after BD −1.38 (−1.74 to −1.05)* −2.00 (−2.54 to −1.47)* −0.99 (−1.41 to −0.56)* .007
SDS RVpleth 0.63 (0.24 to 1.02)* 0.52 (−0.20 to 1.23) 0.74 (0.27 to 1.21)* .781
SDS TLCpleth −0.27 (−0.67 to 0.12) −0.39 (−1.12 to 0.34) −0.31 (−0.81 to 0.19) .205
SDS RV/TLCpleth 0.74 (0.28‐1.20)* 0.63 (−0.23 to 1.50) 0.90 (0.32 to 1.47)* .687
SDS FRCpleth 0.17 (−0.12 to 0.45) 0.04 (−0.44 to 0.52) 0.30 (−0.13 to 0.73) .422
SDS DLCO −0.99 (−1.32 to −0.65)* −1.14 (−1.62 to −0.65)* −0.86 (−1.32‐−0.40)* .367
SDS KCO −1.22 (−1.48 to −0.96)* −1.41 (−1.93 to −0.90)* −1.09 (−1.37 to −0.82)* .217
Data are presented as estimated marginal mean (95% confidence intervals) SDS lung function parameters.
Abbreviations: BD, bronchodilation; CDH, congenital diaphragmatic hernia; DLco, transfer factor for carbon monoxide; ECMO, extracorporeal membrane
oxygenation; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; FEF25‐75, forced expiratory flows between 25% and 75% of vital capacity,
FRCpleth, functional residual capacity; KCO, diffusion capacity corrected for alveolar volume; RVpleth, plethysmographic derived residual volume; SDS,
standard deviation score; TLCpleth, plethysmographic derived total lung capacity.
aMann‐Whitney U tests: differences in lung function parameters between ECMO‐ and non–ECMO‐treated CDH patients
Significantly below/above the population norm (SDS = 0): *P ≤ .001; **P ≤ .01; ***P = .025
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33% to 12% after the introduction of the postnatal treatment
protocol, there might be an increase of the presence of more severe
lung hypoplasia in the survivors. However, ECMO treatment was
more frequent before the introduction of the protocol, and was
usually applied in children with more severe lung hypoplasia. Still,
ECMO‐treated children, who participated in the UK ECMO trial, had
a slightly better lung function than those who were conventionally
ventilated,34 as they might have been spared prolonged ventilation
and consequent barotrauma. Our study included only two CDH
patients treated with ECMO after the implementation of the
postnatal treatment protocol. More patients treated according to
the postnatal treatment protocol should be studied to demonstrate
possible significant effects of this protocol on lung function.
Significant reversibility of airflow obstruction was observed in
almost one‐third of our participants. Our data do not allow for
speculations about the reason for this phenomenon, but it empha-
sizes the importance of long‐term follow‐up of all children with CDH.
Supportive care by pediatric pulmonologists including prescription of
bronchodilators may be useful to reduce pulmonary morbidity and
improve exercise tolerance.35
The strengths of our study are the relatively large cohort and the
longitudinal design. Another strength of our study is the absence of
TABLE 4 Estimated mean differences of lung function parameters from 8 to 12 y in CDH patient treated with and without ECMO
Estimated mean differences (95% CI)
Lung function parameters Total ECMO non‐ECMO
SDS FVC before BD −0.17 (−0.45 to 0.11) −0.11 (−0.47 to 0.26) −0.23 (−0.68 to 0.23)
SDS FVC after BD −0.31 (−0.62 to 0.01) −0.11 (−0.62 to 0.40) −0.48 (−0.92 to ‐0.04)**
SDS FEV1 before BD −0.57 (−0.79 to −0.36)* −0.54 (−0.84 to ‐0.24)* −0.66 (−0.99 to −0.33)*
SDS FEV1 after BD −0.48 (‐0.77 to −0.19)* ‐0.45 (‐0.97 to 0.07) −0.52 (−0.86 to −0.19)**
SDS FEV1/FVC before BD −0.59 (−0.92 to −0.27)* −0.76 (−1.19 to −0.32)* −0.43 (−0.93 to 0.08)
SDS FEV1/FVC after BD −0.25 (−0.61 to 0.10) −0.56 (−1.08 to −0.04)** 0.13 (−0.32 to 0.57)
SDS FEF25‐75 before BD −0.63 (−0.89 to −0.37)* −0.79 (−1.23 to −0.35)* −0.48 (−0.81 to ‐0.14)**
SDS FEF25‐75 before BD −0.45 (−0.75 to −0.16)* −0.58 (−1.11 to −0.05)** −0.31 (−0.66 to 0.04)
SDS RVpleth 0.07 (−0.37 to 0.51) −0.33 (−1.14 to 0.47) 0.35 (−0.16 to 0.85)
SDS TLCpleth −0.27 (−0.58 to 0.04) −0.23 (−0.76 to 0.29) −0.40 (−0.79 to −0.01)
SDS RV/TLCpleth ratio 0.06 (−0.41 to 0.53) −0.37 (−1.13 to 0.39) 0.41 (−0.17 to 0.99)
SDS FRCpleth 0.04 (−0.20 to 0.27) −0.09 (−0.35 to 0.18) 0.17 (−0.27 to 0.60)
SDS DLCO −0.08 (−0.40 to 0.24) 0.25 (−0.17 to 0.66) −0.14 (−0.58 to 0.29)
SDS KCO 0.06 (−0.22 to 0.35) 0.19 (−0.36 to 0.75) 0.05 (−0.27 to 0.37)
Abbreviations: BD, bronchodilation; CDH, congenital diaphragmatic hernia; CI, confidence interval; DLco, transfer factor for carbon monoxide; ECMO,
extracorporeal membrane oxygenation; KCO, diffusion capacity corrected for alveolar volume ; FEV1, forced expiratory volume in 1 s, FEF25‐75, forced
expiratory flows between 25% and 75% of vital capacity; FVC, forced vital capacity; FRCpleth, functional residual capacity, RVpleth, plethysmographic
derived residual volume; SDS, standard deviation score, TLCpleth, plethysmographic derived total lung capacity.
Significant change of estimated mean differences (based on estimated marginal means) from 8 to 12 y: *P ≤ .001; **P ≤ .01
F IGURE 2 FEV1 and FEF25‐75 before bronchodilation from 8 to 12 years. Data shown are linear mixed models estimates of mean values with
95% confidence intervals. Circles: CDH with ECMO, lozenge: CDH without ECMO. CDH, congenital diaphragmatic hernia; ECMO,
extracorporeal membrane oxygenation; FEV1, forced expiratory volume in 1 second;FEF25‐75, forced expiratory flows between 25% and 75% of
vital capacity; SDS, standard deviation score
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significant differences in baseline data reflecting severity of illness
between the participants and nonparticipants of our follow‐up
program. Selection bias is therefore unlikely.
Several limitations need to be addressed, however. First, data of only
a relatively small number of children assessed at 12 years of age (n = 37)
were included, although mixed models account for data missing at
random. Secondly, although we had a large number of reliable lung
function tests, some lung function assessment data were missing
(flowchart), mainly concerning children with no previous experience in
lung function testing. Thirdly, we found a significant effect of the use of
the postnatal treatment protocol on lung function. Children treated after
the introduction of the postnatal treatment protocol had more severe
airflow obstruction than the children treated before. A larger sample size
of 8‐ and 12‐year‐olds is needed to unravel the relation between the
introduction of the postnatal treatment protocol, severity of lung
hypoplasia, microstructural pulmonary changes of the lungs, and airflow
obstruction. Finally, patient‐reported outcomes such as atopy and lower
respiratory tract infections (RTIs) treated with antibiotics and/or
gastroesophageal reflux (Table 2), were not considered as covariates in
the linear mixed model, because only a small number of patients reported
those complaints. To minimize the risk of recall bias, we recorded only the
number of RTIs treated with antibiotics in the last year. Digital exchange
of information of prescribed antibiotics between family physician,
pharmacy, and hospital could contribute to reliable monitoring of the
individual use of antibiotics over several years.
In conclusion, airflow obstruction deteriorates over time, though
reduced diffusion capacity remains stable. These observations are
irrespective of ECMO treatment. Good pulmonary care into
adulthood should be provided to minimize respiratory dysfunction
on the long term. Early risk stratification may be important to offer
timely intervention.
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